695 | CLINICAL RESPONSE AND SAFETY FOR RELAPSED/REFRACTORY CENTRAL NERVOUS SYSTEM DIFFUSE LARGE B CELL LYMPHOMA TREATED BY RADIOTHERAPY SEQUENTIAL GLOFITMAB

Documenti analoghi

• 621 | EFFICACY AND SAFETY OF GLOFITAMAB COMBINED WITH TISLELIZUMAB IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: A PILOT STUDY IN CHINA
  di: D. Zhou, et al.
  Pubblicazione: (2025)
• 632 | EFFICACY AND SAFETY OF POLA‐ICE, WITH OR WITHOUT RITUXIMAB IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: A REAL‐WORLD SINGLE CENTER STUDY
  di: H. Huang, et al.
  Pubblicazione: (2025)
• 666 | OUTCOMES OF RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA IN AN ASIAN MULTIETHNIC COHORT
  di: N. Lim, et al.
  Pubblicazione: (2025)
• 88 | TIRABRUTINIB FOR THE TREATMENT OF RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: EFFICACY AND SAFETY FROM THE PHASE II PROSPECT STUDY
  di: L. Nayak, et al.
  Pubblicazione: (2025)
• 341 | IBRUTINIB FOR THE TREATMENT OF RELAPSED/REFRACTORY PRIMARY OR SECONDARY CENTRAL NERVOUS SYSTEM LARGE B‐CELL LYMPHOMAS: EXPERIENCE FROM THE GELTAMO GROUP
  di: D. Alonso Castronuño, et al.
  Pubblicazione: (2025)